Shares of Unity Biotechnology, Inc. (NASDAQ:UBX – Get Ranking) have been given an normal advice of “Buy” from the seven research corporations that are now masking the company, MarketBeat Ratings stories. One particular investigate analyst has rated the stock with a maintain rating and 5 have offered a obtain rating to the business. The regular 12-month concentrate on cost amongst analysts that have current their coverage on the inventory in the final 12 months is $6.33.
UBX has been the subject matter of a range of modern analyst experiences. Zacks Investment Study downgraded shares of Unity Biotechnology from a “buy” ranking to a “hold” score in a report on Wednesday, Might 18th. Citigroup dropped their price target on shares of Unity Biotechnology from $6.00 to $5.00 and established a “na” rating on the stock in a report on Tuesday, Might 17th.
UBX inventory traded up $.00 for the duration of investing on Wednesday, hitting $.70. 4,269 shares of the inventory traded hands, in contrast to its typical volume of 253,259. Unity Biotechnology has a 1 12 months minimal of $.66 and a 1 yr significant of $5.05. The firm’s 50 day going typical is $.92 and its two-hundred working day transferring ordinary is $1.19. The inventory has a current market cap of $48.42 million, a cost-to-earnings ratio of -.65 and a beta of .40.
Unity Biotechnology (NASDAQ:UBX – Get Ranking) very last declared its quarterly earnings information on Tuesday, May possibly 10th. The enterprise claimed ($.28) EPS for the quarter, lacking the consensus estimate of ($.26) by ($.02). As a team, equities investigation analysts foresee that Unity Biotechnology will submit -1.1 EPS for the existing fiscal year.
Institutional buyers have just lately added to or decreased their stakes in the business. LPL Financial LLC acquired a new stake in shares of Unity Biotechnology through the fourth quarter valued at about $26,000. Virtu Money LLC obtained a new placement in Unity Biotechnology all through the fourth quarter well worth $78,000. Walleye Funds LLC boosted its stake in Unity Biotechnology by 331.2% all through the fourth quarter. Walleye Capital LLC now owns 54,365 shares of the company’s inventory well worth $79,000 right after shopping for an extra 41,758 shares throughout the time period. Goldman Sachs Team Inc. boosted its stake in Unity Biotechnology by 116.3% during the fourth quarter. Goldman Sachs Team Inc. now owns 90,164 shares of the company’s stock worth $132,000 immediately after acquiring an further 48,483 shares throughout the time period. Eventually, Connor Clark & Lunn Expense Management Ltd. purchased a new posture in Unity Biotechnology throughout the fourth quarter truly worth $138,000. Hedge money and other institutional buyers own 21.22% of the company’s inventory.
About Unity Biotechnology (Get Ranking)
Unity Biotechnology, Inc, a biotechnology business, engages in the investigate and enhancement of therapeutics to sluggish, halt, or reverse conditions of aging. The firm’s guide drug candidate incorporates UBX1325, which is Section II clinical trial for the remedy of age-relevant health conditions of the eye, together with diabetic macular edema, age-relevant macular degeneration, and diabetic retinopathy.
Obtain News & Rankings for Unity Biotechnology Everyday – Enter your electronic mail deal with below to receive a concise everyday summary of the most recent news and analysts’ ratings for Unity Biotechnology and similar companies with MarketBeat.com’s Cost-free every day electronic mail newsletter.